26th Mar 2008 12:08
ABCAM Plc26 March 2008 For immediate release 26 March 2008 ABCAM PLC ("Abcam" or "the Company") Shareholding Cambridge UK, 26 March 2008: Abcam Plc announces that in accordance with theFSA's Disclosure and Transparency Rules, the Company has been notified on 25March 2008 that as at 13 March 2008, Artemis Investment Management Limited has adirect interest in voting rights over 2,195,081 ordinary shares of 1p each inthe Company amounting to approximately 6.27% of the issued share capital of theCompany. For further information please contact: Abcam + 44 (0) 1223 696000Jonathan Milner, Chief Executive OfficerJeff Iliffe, Chief Financial Officerwww.abcam.com Numis Securities +44 (0) 20 7260 1000James BlackNick Westlake Buchanans Communications +44 (0) 20 7466 5000Mark Court / Mary-Jane Johnson Notes for editors: About Abcam plcAbcam is a producer and distributor of research-grade antibodies headquarteredin Cambridge, UK, with a US office located in Cambridge Massachusetts and aJapanese office in Tokyo. Abcam was admitted to AIM in November 2005 and tradesunder the ticker symbol ABC. The Company produces and distributes its own andthird party produced antibodies to academic and commercial users throughout theworld with product information provided and ordering available through theCompany's website, www.abcam.com. The antibodies are sold under the Abcam brandname. The Company's vision is to build the largest online antibody resource inthe world while also ensuring that the antibodies are of high quality andcommercially viable. Abcam now has an online catalogue of approximately 41,000products, most of which are antibodies, from over 200 suppliers supported byup-to-date and detailed technical data sheets, which are created by the Company.The Company currently employs 168 staff in its three operating companies. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
ABC.L